Your browser doesn't support javascript.
Aspirin Is Related to Worse Clinical Outcomes of COVID-19.
Kim, Isaac; Yoon, Siyeong; Kim, Minsup; Lee, Hyunil; Park, Sinhyung; Kim, Wonsang; Lee, Soonchul.
  • Kim I; Department of General Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13488, Korea.
  • Yoon S; Department of Orthopedic Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13488, Korea.
  • Kim M; inCerebro Drug Discovery Institute, Seoul Technopark, Seoul 01811, Korea.
  • Lee H; Department of Orthopedic Surgery, Ilsan Paik Hospital, Inje University, Goyang 10380, Korea.
  • Park S; Department of Orthopedic Surgery, Bucheon Hospital, Soonchunhyang University, Bucheon 14584, Korea.
  • Kim W; inCerebro Drug Discovery Institute, Seoul Technopark, Seoul 01811, Korea.
  • Lee S; Department of Orthopedic Surgery, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam 13488, Korea.
Medicina (Kaunas) ; 57(9)2021 Sep 04.
Article in English | MEDLINE | ID: covidwho-1390697
ABSTRACT
Backgroundand

Objectives:

Aspirin is used globally to reduce pain and inflammation; however, its effect in patients with coronavirus disease (COVID-19) is not fully investigated and remains controversial. We evaluated the association between aspirin and COVID-19 outcomes using nationwide data from the Korean National Health Insurance System. Materials and

Methods:

This was a retrospective observational cohort study that included 22,660 eligible patients who underwent COVID-19 testing in South Korea between 1 January-31 July 2020. We identified all aspirin users prescribed aspirin within two weeks before or after the index date. The primary outcome was positivity for the COVID-19 test, and secondary outcomes included conventional oxygen therapy, intensive care unit, mechanical ventilation, or death. We applied the propensity score matching method to reduce the possible bias originating from the differences in patients' baseline characteristics.

Results:

Of those eligible, 662 patients were prescribed aspirin. Among them, 136 patients were on aspirin within two weeks before diagnosis and 526 patients were on aspirin after diagnosis. The COVID-19 test positivity rate was not significantly different according to aspirin use. Aspirin use before COVID-19 was related to an increased death rate and aspirin use after COVID-19 was related to a higher risk of the conventional oxygen therapy.

Conclusion:

Aspirin use was associated with adverse effects in COVID-19 patients. Further studies for mechanisms are needed.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Aspirin / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal subject: Medicine Year: 2021 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Aspirin / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal subject: Medicine Year: 2021 Document Type: Article